Capital Flow Monitor · Sponsors · CIK 1782959
Capital Rx, Inc.
228 PARK AVENUE S., NEW YORK, NY, 10003 · 855-538-8897
Other · Corporation· inc. DELAWARE true
Fit score
—
Offering
$232.9M
Sold
$230.8M
% sold
99.1%
Investors
8
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-09-26 | D ·current | 506(b) | $232.9M | $230.8M | 99.1% | 8 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- A. J. Loiacono — Executive Officer / Director, New York, NY
- Ryan Kelly — Director, New York, NY
-
Lenard Marcus — Director, New York, NY
1 other raise
- Field Effect Software Inc. $3.0M of $3.0M · 100.0%
-
Kevin Hill — Director, New York, NY
1 other raise
- zizzl holding company, inc. $1.5M of $1.5M · 100.0%
-
Jared Kesselheim — Director, New York, NY
8 other raises
- Transformation Capital Executive Fund IV, L.P. $0 of —
- Golden Eagle Opportunities, L.P. $0 of —
- Transformation Capital Partners III-CPRX, L.P. $0 of —
- TRANSFORMATION CAPITAL CO-INVESTMENT FUND III, L.P. $15.7M of —
- Transformation Capital Fund IV-A, L.P. $0 of —
- Transformation Capital Fund IV, L.P. $0 of —
- Transformation Capital Fund IV (Cayman Feeder), L.P. $0 of —
- Care.Stat!, Inc. $5.3M of $21.2M · 24.7%
-
Robert Mittendorff — Director, New York, NY
3 other raises
- Numerion Labs, Inc. $19.8M of $35.0M · 56.6%
- Solve Therapeutics, Inc. $48.2M of $120.5M · 40.0%
- Volastra Therapeutics, Inc. $30.1M of $30.1M · 100.0%
- Daniel Delmastro — Director, New York, NY
- Mark Kandrysawtz — Director, New York, NY
- Mostafa Kamal — Director, New York, NY
-
Holly Maloney — Director, New York, NY
4 other raises
- NewDays, Inc. $8.5M of $9.0M · 94.4%
- Equip Health, Inc. $54.1M of $61.6M · 87.8%
- Cartwheel Care Inc. $35.2M of $44.0M · 79.9%
- Sprinter Health, Inc. $55.0M of $55.0M · 100.0%
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.